Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

221. Screening, Monitoring, and Treatment of Stage 1-3 Chronic Kidney Disease: A Clinical Practice Guideline from the American College of Physicians

Screening, Monitoring, and Treatment of Stage 1-3 Chronic Kidney Disease: A Clinical Practice Guideline from the American College of Physicians Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register (...) and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 17 December 2013 Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Robert H. Hopkins Jr., MD; Donna E. Sweet, MD; Melissa Starkey, PhD; Paul Shekelle, MD, PhD; for the Clinical

American College of Physicians2013

222. Chronic kidney disease and measurement of albuminuria and proteinuria - a position statement

Chronic kidney disease and measurement of albuminuria and proteinuria - a position statement Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement | Medical Journal of Australia Search form Search Articles Topics MJA team Author centre Multimedia Centenary Place an ad secondlevel Clinical focus Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement David W Johnson, Graham R D Jones, Timothy H Mathew, Marie J Ludlow (...) , Stephen J Chadban, Tim Usherwood, Kevan Polkinghorne, Stephen Colagiuri, George Jerums, Richard MacIsaac and Helen Martin, Australasian Proteinuria Consensus Working Group Med J Aust 2012; 197 (4): 224-225. doi: 10.5694/mja11.11468 Summary Optimal detection and subsequent risk stratification of people with chronic kidney disease (CKD) requires simultaneous consideration of both kidney function (glomerular filtration rate [GFR]) and kidney damage (as indicated by albuminuria or proteinuria

Clinical Practice Guidelines Portal2012

223. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate - new developments and revised recommendations

Chronic kidney disease and automatic reporting of estimated glomerular filtration rate - new developments and revised recommendations Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations | Medical Journal of Australia Search form Search Articles Topics MJA team Author centre Multimedia Centenary Place an ad secondlevel Clinical focus Chronic kidney disease and automatic reporting of estimated (...) in automatic reporting of estimated glomerular filtration rate (eGFR) with requests for serum creatinine concentration in adults, facilitated the unification of units of measurement for creatinine and eGFR, and promoted the standardisation of assays. New advancements and continuing debate led the Australasian Creatinine Consensus Working Group to reconvene in 2010. The working group recommends that the method of calculating eGFR should be changed to the Chronic Kidney Disease Epidemiology Collaboration

Clinical Practice Guidelines Portal2012

225. Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease ? first or second line

Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease ? first or second line Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease – first or second line Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease – first or second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Ferumoxytol (Feraheme) for iron deficiency anaemia not associated with chronic kidney disease – first or second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anemia, Iron-Deficiencys Language Published English Country of organisation England English summary An English language summary is available

Health Technology Assessment (HTA) Database.2012

226. Peginesatide for anaemia in chronic kidney disease ? first and second line

Peginesatide for anaemia in chronic kidney disease ? first and second line Peginesatide for anaemia in chronic kidney disease – first and second line Peginesatide for anaemia in chronic kidney disease – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Peginesatide for anaemia in chronic kidney (...) disease – first and second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Anemia; Chronic Disease; Hematinicss; Kidney Diseases; Peptides Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School

Health Technology Assessment (HTA) Database.2012

227. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis Upadhyay A, Earley A, Lamont A, Haynes S, Wanner C, Balk EM CRD summary The authors concluded that lipid-lowering therapy reduced rates of cardiac death and cardiovascular events in people (...) with chronic kidney disease. The review was well conducted; having a large number of patients. It is possible that results in patients with mild disease may not extend to those with advanced disease, but the authors’ conclusions are likely to be reliable. Authors' objectives To investigate the effectiveness of lipid-lowering therapy on clinical outcomes for patients with chronic kidney disease. Searching MEDLINE and The Cochrane library were searched from January 2000 to November 2011, without language

DARE.2012

228. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis Palmer SC, Craig JC, Navaneethan S, Tonelli M, Pellegrini F, Strippoli GF CRD summary This well-conducted review concluded that statins decreased (...) mortality and cardiovascular events in persons with early stages of chronic kidney disease, had little or no effect in people who received dialysis and had uncertain effects in kidney transplant recipients. The authors' conclusions reflect the evidence available and appear likely to be reliable. Authors' objectives To assess the benefits and harms of statin therapy for adults with chronic kidney disease and examine whether effects varied by stage of disease. Searching Studies were identified from

DARE.2012

229. Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement.

Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement. DESCRIPTION: New U.S. Preventive Services Task Force (USPSTF) recommendation statement on screening for chronic kidney disease (CKD). METHODS: The USPSTF reviewed evidence on screening for CKD, including evidence on screening, accuracy of screening, early treatment, and harms of screening and early treatment. POPULATION: This recommendation applies to asymptomatic adults without diagnosed CKD (...) . Testing for and monitoring CKD for the purpose of chronic disease management (including testing and monitoring patients with diabetes or hypertension) are not covered by this recommendation. RECOMMENDATION: The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of routine screening for CKD in asymptomatic adults (I statement).

Annals of Internal Medicine2012

230. Review: Antiplatelet therapy does not reduce mortality in chronic kidney disease.

Review: Antiplatelet therapy does not reduce mortality in chronic kidney disease. ACP Journal Club: review: antiplatelet therapy does not reduce mortality in chronic kidney disease. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create (...) File 1 selected item: 22910962 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Aug 21;157(4):JC2-8. doi: 10.7326/0003-4819-157-4-201208210-02008. ACP Journal Club: review: antiplatelet therapy does not reduce mortality in chronic kidney disease. 1 . 1 Johns Hopkins Medical Institutions Baltimore, Maryland, USA. Comment

Annals of Internal Medicine2012

231. A risk score for chronic kidney disease in the general population

A risk score for chronic kidney disease in the general population 22340925 2012 02 20 2012 04 03 2016 12 03 1555-7162 125 3 2012 Mar The American journal of medicine Am. J. Med. A risk score for chronic kidney disease in the general population. 270-7 10.1016/j.amjmed.2011.09.009 Stratification of individuals at risk for chronic kidney disease may allow optimization of preventive measures to reduce disease incidence and complications. We sought to develop a risk score that estimates (...) an individual's absolute risk of incident chronic kidney disease. Framingham Heart Study participants free of baseline chronic kidney disease, who attended a baseline examination in 1995-1998 and follow-up in 2005-2008, were included in the analysis (n = 2490). Chronic kidney disease was defined as an estimated glomerular filtration rate <60 mL/min/1.73 m(2) using the Modification of Diet in Renal Disease equation. Participants were assessed for the development of chronic kidney disease at 10 years follow-up

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

232. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. BACKGROUND: Diabetes is regarded as a coronary heart disease risk equivalent-ie, people with the disorder have a risk of coronary events similar to those with previous myocardial infarction. We assessed whether chronic kidney disease should be regarded as a coronary heart disease risk equivalent. METHODS: We studied a population-based cohort with measures (...) of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. We used validated algorithms based on hospital admission and medical-claim data to classify participants with baseline history of myocardial infarction or diabetes and to ascertain which patients were admitted to hospital for myocardial infarction during follow-up (the primary outcome). For our primary analysis, we defined baseline chronic kidney disease as eGFR 15-59·9 mL/min per 1·73 m(2) (stage 3 or 4 disease). We used

Lancet2012

233. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive services task force and for an american college of physicians clinical practice guideline

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive services task force and for an american college of physicians clinical practice guideline Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians clinical practice guideline Screening for, monitoring, and treatment of chronic kidney disease (...) stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians clinical practice guideline Fink HA, Ishani A, Taylor BC, Greer NL, Macdonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ CRD summary This review concluded that evidence for treatment benefit in chronic kidney disease was strongest for angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers and in patients with albuminuria combined with diabetes

DARE.2012

235. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Vegter S, Tolley K, Keith MS, Postma MJ Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of the non-calcium-based phosphate binder lanthanum carbonate, as a second-line treatment for hyperphosphataemia, after the failure of calcium-based binders, for patients with chronic kidney disease who had

NHS Economic Evaluation Database.2012

236. Prevalence of chronic kidney disease in China: a cross-sectional survey.

Prevalence of chronic kidney disease in China: a cross-sectional survey. BACKGROUND: The prevalence of chronic kidney disease is high in developing countries. However, no national survey of chronic kidney disease has been done incorporating both estimated glomerular filtration rate (eGFR) and albuminuria in a developing country with the economic diversity of China. We aimed to measure the prevalence of chronic kidney disease in China with such a survey. METHODS: We did a cross-sectional survey (...) of a nationally representative sample of Chinese adults. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2) or the presence of albuminuria. Participants completed a lifestyle and medical history questionnaire and had their blood pressure measured, and blood and urine samples taken. Serum creatinine was measured and used to estimate glomerular filtration rate. Urinary albumin and creatinine were tested to assess albuminuria. The crude and adjusted prevalence of indicators of kidney

Lancet2012

237. Chronic kidney disease stages 1?3: screening, monitoring, and treatment

Chronic kidney disease stages 1?3: screening, monitoring, and treatment Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald, R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald, R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 37. 2012 Authors' objectives The objective was to systematically review and synthesize evidence regarding benefits and harms of screening for and monitoring and treatment of chronic kidney disease (CKD

Health Technology Assessment (HTA) Database.2012

238. Systematic review: Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters

Systematic review: Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies (...) . Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cochrane review: in adults with chronic kidney disease regular exercise improves

Evidence-Based Nursing (Requires free registration)2012

240. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease

Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 83. 2012 Authors' objectives To summarize the literature on the use of newer versus classical laboratory biomarkers of iron status as part of the management strategies for iron deficiency in stages 3

Health Technology Assessment (HTA) Database.2012